DK1149111T3 - Fremgangsmåde og sammensætning til inhibering af angiogenese - Google Patents

Fremgangsmåde og sammensætning til inhibering af angiogenese

Info

Publication number
DK1149111T3
DK1149111T3 DK00904246T DK00904246T DK1149111T3 DK 1149111 T3 DK1149111 T3 DK 1149111T3 DK 00904246 T DK00904246 T DK 00904246T DK 00904246 T DK00904246 T DK 00904246T DK 1149111 T3 DK1149111 T3 DK 1149111T3
Authority
DK
Denmark
Prior art keywords
type
antagonists
methods
vivo
inhibiting angiogenesis
Prior art date
Application number
DK00904246T
Other languages
English (en)
Inventor
Peter Brooks
Eric Petitclerc
Xu Jingsong
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of DK1149111T3 publication Critical patent/DK1149111T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
DK00904246T 1999-01-06 2000-01-06 Fremgangsmåde og sammensætning til inhibering af angiogenese DK1149111T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11487799P 1999-01-06 1999-01-06
US11487899P 1999-01-06 1999-01-06
US14353499P 1999-07-13 1999-07-13
US15249699P 1999-09-02 1999-09-02
PCT/US2000/000383 WO2000040597A1 (en) 1999-01-06 2000-01-06 Method and composition for angiogenesis inhibition

Publications (1)

Publication Number Publication Date
DK1149111T3 true DK1149111T3 (da) 2009-12-14

Family

ID=27493978

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00904246T DK1149111T3 (da) 1999-01-06 2000-01-06 Fremgangsmåde og sammensætning til inhibering af angiogenese

Country Status (13)

Country Link
US (4) US7122635B2 (da)
EP (1) EP1149111B1 (da)
JP (2) JP2002539076A (da)
CN (1) CN1345331A (da)
AT (1) ATE439369T1 (da)
AU (1) AU776137B2 (da)
CA (1) CA2358517C (da)
CY (1) CY1109616T1 (da)
DE (1) DE60042731D1 (da)
DK (1) DK1149111T3 (da)
ES (1) ES2333845T3 (da)
PT (1) PT1149111E (da)
WO (1) WO2000040597A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US7687462B2 (en) 1999-10-05 2010-03-30 The Regents Of The University Of California Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition
JP5859179B2 (ja) * 2000-03-15 2016-02-10 オーバスネイチ メディカル、インコーポレイテッド 内皮細胞接着を促進するコーティング
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
EP1423080A4 (en) * 2001-03-01 2009-06-03 Conforma Therapeutics Corp PROCESS FOR TREATING PROLIFERATIVE GENETIC DISORDERS WITH HSP90 INHIBITORS
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
CN1984999A (zh) * 2003-01-29 2007-06-20 纽约州立大学研究基金会 耐受诱导的靶向抗体产生
US7662783B2 (en) * 2003-02-20 2010-02-16 New York University CLK-peptide and SLK-peptide
US7601694B2 (en) 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
US7387998B2 (en) * 2003-03-28 2008-06-17 New York University STQ peptides
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
WO2006089218A2 (en) * 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating angiogenesis
US20060240002A1 (en) * 2005-03-11 2006-10-26 Brooks Peter C Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components
US20060216237A1 (en) * 2005-03-11 2006-09-28 Brooks Peter C Inhibition of angiogenesis and tumor development by IGFBP-4
US20060216236A1 (en) * 2005-03-11 2006-09-28 Brooks Peter C Methods of inhibiting alphavBeta3-mediated angiogenesis and tumor development
BRPI0609509A2 (pt) * 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
AU2006283174A1 (en) * 2005-08-24 2007-03-01 Cell-Matrix, Inc. Combination therapies for inhibiting integrin-extracellular matrix interactions
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
EP2054442A2 (en) * 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denatured collagen peptides and uses thereof
US20120237504A1 (en) 2009-10-20 2012-09-20 Maine Medical Center Compositions and methods for treating inflammation and fibrosis
EP2647301B1 (en) 2010-05-06 2019-08-28 R.J. Reynolds Tobacco Company Segmented smoking article
EP2639243A4 (en) * 2010-11-10 2014-06-04 Nippon Kayaku Kk ANTIBODIES AGAINST UNIVERSAL TYPE IV COLLAGEN POLYPEPTIDE AND PHARMACEUTICAL OR ACTIVE SUBSTANCE FOR THE DIAGNOSIS, PREVENTION OR TREATMENT OF TUMORS THEREOF
JP2016509863A (ja) * 2013-03-15 2016-04-04 ラーソン、マルクス カーレ、トールレイフＬＡＲＳＳＯＮ， Ｍａｒｃｕｓ Ｋａｒｅ， Ｔｏｒｌｅｉｆ 細胞、臍帯血収集のための方法及び装置、並びに細胞の単離のための方法及び装置
GB201413357D0 (en) * 2014-07-28 2014-09-10 Philogen Spa Antibodies for treatment and diagnosis
AU2016270710A1 (en) * 2015-06-01 2017-12-14 Maine Medical Center Research Institute Enhancing the therapeutic activity of an immune checkpoint inhibitor
US10906977B2 (en) 2016-02-18 2021-02-02 Maine Medical Center Research Institute Enhancing the therapeutic activity of immune checkpoint inhibitor
WO2018073615A1 (en) 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
CN108484763A (zh) * 2018-04-03 2018-09-04 东莞光极生物科技有限公司 L7d8单克隆抗体及其应用
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2020256628A1 (en) 2019-06-20 2020-12-24 Amniotics Ab An apparatus for filtering amniotic fluid
JP7714535B2 (ja) 2019-10-18 2025-07-29 アムニオティクス・アーベー 羊水およびそれに由来する細胞から羊水間葉系幹細胞を得るためのプロセスならびに装置
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
WO2023079183A1 (en) * 2021-11-08 2023-05-11 Nordic Bioscience A/S A method for detecting cancer in a patient
WO2023201027A1 (en) * 2022-04-14 2023-10-19 Omeat Inc. Systems and methods for protein recovery from cell culture media

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300434A (en) * 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
JP3105629B2 (ja) * 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
US6132976A (en) 1992-12-04 2000-10-17 Shriners Hospitals For Children Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
CA2148132A1 (en) 1992-12-04 1994-06-23 Anthony Robin Poole Immunoassay for the measurement of collagen cleavage in cartilage
US5541295A (en) * 1993-02-12 1996-07-30 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Detection of type II collagen and its peptides
EP0711415B1 (de) * 1993-07-28 1998-07-22 Boehringer Mannheim Gmbh Immunoassay zum nachweis von kollagen typ i oder kollagenfragmenten davon
US5763272A (en) 1994-12-23 1998-06-09 Boehringer Mannheim Gmbh Hybridoma for producing antibody for collagen I
WO1997044059A2 (en) * 1996-05-23 1997-11-27 Shriner's Hospitals For Children Cartilage type ii collagen as an angiogenic factor
US6492508B1 (en) * 1996-06-03 2002-12-10 United States Surgical Corp. A Division Of Tyco Healthcare Group Nucleic acids encoding extracellular matrix proteins
GB9702252D0 (en) * 1997-02-06 1997-03-26 Univ Sheffield Medical The Sch Collagen assay
US5972623A (en) * 1997-07-31 1999-10-26 Metra Biosystems, Inc. Collagen-peptide assay method
US6030792A (en) 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
US6833373B1 (en) * 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth

Also Published As

Publication number Publication date
US8025883B2 (en) 2011-09-27
US20030113331A1 (en) 2003-06-19
WO2000040597A1 (en) 2000-07-13
JP2002539076A (ja) 2002-11-19
EP1149111A4 (en) 2004-08-11
US7588760B2 (en) 2009-09-15
DE60042731D1 (de) 2009-09-24
US7122635B2 (en) 2006-10-17
US20090028867A1 (en) 2009-01-29
CY1109616T1 (el) 2014-08-13
EP1149111B1 (en) 2009-08-12
CN1345331A (zh) 2002-04-17
CA2358517A1 (en) 2000-07-13
US20060088540A1 (en) 2006-04-27
ATE439369T1 (de) 2009-08-15
US20060067932A1 (en) 2006-03-30
PT1149111E (pt) 2009-11-19
AU2603200A (en) 2000-07-24
JP2011084566A (ja) 2011-04-28
AU776137B2 (en) 2004-08-26
US7345151B2 (en) 2008-03-18
EP1149111A1 (en) 2001-10-31
WO2000040597A9 (en) 2001-08-30
CA2358517C (en) 2012-10-09
ES2333845T3 (es) 2010-03-02

Similar Documents

Publication Publication Date Title
CY1109616T1 (el) Μεθοδος και συνθεση για αναστολη αγγειογενεσης
Samuel Relaxin: antifibrotic properties and effects in models of disease
EA200300845A1 (ru) Модифицированные антитела и способы применения
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
DK0987998T3 (da) Decellulering af væv
DE60238782D1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
MXPA05007843A (es) Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes.
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
EE200100549A (et) Meetod fibroosi ravimiseks integriini alfa-4 subühiku antagonistide abil
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
WO2004073649A3 (en) Clk-peptide and slk-peptide
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
Ashford et al. The modern surgical and non-surgical management of appendicular skeletal metastases
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
Aguzzi et al. Intracellular targets of RGDS peptide in melanoma cells
PT866870E (pt) Proteinas de fusao factor tecidual-dominio de kunitz como inibidores do factor viia
ATE480552T1 (de) Stq-peptide
WO2001004157A3 (en) NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS
DK1173766T3 (da) Isoform af tenascin-C som markör for neoplasier
EA200401137A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
RU2006100030A (ru) Способ ингибирования рецепторных тирозинкиназ с помощью внеклеточного антагониста и внутриклеточного антагониста